UNSPSC 51322502: Treloxinate

This classification denotes an anti-lipidemic agent with the molecular formula C16H12Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YA71JCD50, chemically known as 2,10-dichloro-12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, methyl ester but generally known as treloxinate, which bears US NIH Compound Identifier 35678. European Medicines Agency schedules Treloxinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11231MIG.

UNSPSC 51322502 Treloxinate (Commodity) encompasses advanced life support medications and generic pharmaceuticals procured by state and local health authorities, emergency services, and multistate cooperative purchasing alliances. State and local governments buy under this code to supply emergency medical services, hospital systems, and public health programs with critical-care injectable medications and over-the-counter products. The issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations that aggregate demand across multiple jurisdictions. Recent solicitations show a mix of direct procurement by city purchasing offices and RFP-based contracting through cooperative vehicles that serve both state agencies and subordinate local governments.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol HCl 100mg vials, Epinephrine 1:10,000 injections, Adenosine 6mg vials, and Diltiazem 25mg vials) to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the procurement included a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) to participating state and local facilities including Oregon, with a response deadline of March 26, 2026 and a two-year contract term effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploratory procurement development for future formal solicitation.